Future directions in castrate-resistant prostate cancer therapy

Clinical Genitourinary Cancer

Volumn 8, Issue 1, 2010, Pages 37-46

  Antonarakis, Emmanuel ^a   Carducci, Michael ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Clinical trials; CRPC; Drug development; Targeted therapy

Indexed keywords

1 (2 METHOXYETHOXY) 2 METHYL 3 (2 PYRAZINYLMETHYL)NAPHTHO[2,3 D]IMIDAZOLE 4,9 DIONE; AFLIBERCEPT; AZACITIDINE; BEVACIZUMAB; CIXUTUMUMAB; CUSTIRSEN; DASATINIB; DOCETAXEL; EVEROLIMUS; FIGITUMUMAB; ISOSORBIDE; ITRACONAZOLE; LENALIDOMIDE; LY 2181308; MK 2206; OLAPARIB; PANOBINOSTAT; PERIFOSINE; PLACEBO; RIDAFOROLIMUS; SARACATINIB; SORAFENIB; SUNITINIB; TASQUINIMOD; TEMSIROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; VADIMEZAN; VATALANIB; VELIPARIB; VISMODEGIB;

ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS; ALLERGIC REACTION; ANDROGEN DEPRIVATION THERAPY; ANOREXIA; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CASTRATE RESISTANT PROSTATE CANCER; CLINICAL EVALUATION; CYTOPENIA; DIARRHEA; DIZZINESS; DRUG DOSE ESCALATION; DRUG MECHANISM; DYSGEUSIA; DYSPEPSIA; DYSPHONIA; EDEMA; EPISTAXIS; FATIGUE; FEVER; FOOT EDEMA; GASTROINTESTINAL DISEASE; HAND FOOT SYNDROME; HEADACHE; HEART MUSCLE ISCHEMIA; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPERTRIGLYCERIDEMIA; HYPOKALEMIA; HYPOPHOSPHATEMIA; INJECTION SITE REACTION; KIDNEY FAILURE; LEUKOPENIA; MACULOPAPULAR RASH; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MUCOSA INFLAMMATION; MUSCULOSKELETAL PAIN; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEINURIA; PROTHROMBIN TIME; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RIGOR; SIDE EFFECT; SOLID TUMOR; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

EID: 78651064011     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.3816/CGC.2010.n.006     Document Type: Review

References (109)

1. Duque JL, Loughlin KR, Adam RM, et al. Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology 1999; 54:523-7.
2. George DJ, Halabi S, Shepard TF, et al. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res 2001; 7:1932-6.
3. Fox WD, Higgins B, Maiese KM, et al. Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer. Clin Cancer Res 2002; 8:3226-31.
4. Sweeney P, Karashima T, Kim SJ, et al. Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production. Clin Cancer Res 2002; 8:2714-24.
5. Picus J, Halabi S, Rini B, et al. The use of bevacizumab with docetaxel and estramustine in hormone refractory prostate cancer (HRPC): Initial results of CALGB 90006. Proc Am Soc Clin Oncol 2003; 22(suppl):22s (abstract 1578).
6. Di Lorenzo G, Figg WD, Fossa SD, et al. Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: A phase 2 study. Eur Urol 2008; 54:1089-96
7. Kelly WK, Halabi S, Carducci MA, et al. A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): Survival results of CALGB 90401. J Clin Oncol 2010; 28(15 suppl):344s (abstract LBA4511).
8. Dahut WL, Scripture C, Posadas E, et al. A phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin Cancer Res 2008; 14:209-14.
9. Aragon-Ching JB, Jain L, Gulley JL, et al. Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. BJU Int 2009; 103:1636-40
10. Dror Michaelson M, Regan MM, Oh WK, et al. Phase II study of sunitinib in men with advanced prostate cancer. Ann Oncol 2009; 20:913-20.
11. Sonpavde G, Periman PO, Bernold D, et al. Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy. Ann Oncol 2010; 21:319-24
12. Chu QS. Aflibercept: An alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors. Expert Opin Biol Ther 2009; 9:263-71.
13. Isambert N, Freyer G, Zanetta S, et al. A phase I dose escalation and pharmacokinetic (PK) study of intravenous aflibercept (VEGF trap) plus docetaxel in patients with advanced solid tumors: Preliminary results. J Clin Oncol 2008; 26(15 suppl):177s (abstract 3599).
14. Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 2004; 4:314-22.
15. Figg WD, Dahut W, Duray P, et al. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in androgen-independent prostate cancer. Clin Cancer Res 2001; 7:1888-93.
16. Dahut WL, Gulley JL, Arlen PM, et al. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol 2004; 22:2532-9.
17. Ning YM, Gulley JL, Arlen PM, et al. Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2010; 28:2070-6.
18. Dreicer R, Garcia J, Smith S, et al. Phase I/II trial of GM-CSF and lenalidomide in patients with hormone refractory prostate cancer. J Clin Oncol 2007; 25(18 suppl):651s (abstract 15515).
19. Garcia JA, Triozzi P, Elson P, et al. Clinical activity of ketoconazole and lenalidomide in castrate progressive prostate carcinoma: Preliminary results of a phase II trial. J Clin Oncol 2008; 26(15 suppl):285s (abstract 5143).
20. Petrylak DP, Resto-Garces K, Tibyan M, et al. A phase I open-label study using lenalidomide and docetaxel in castration-resistant prostate cancer. J Clin Oncol 2009; 27(suppl): (abstract 5156
21. Lestingi TM, Tolzien K, Kelby SK, et al. Safety and activity of lenalidomide in elderly patients with chemotherapy-naive, castration-resistant prostate cancer (CRPC). J Clin Oncol 2010; 28(15 suppl): (abstract e15125).
22. Isaacs JT, Pili R, Qian DZ, et al. Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer. Prostate 2006; 66:1768-78.
23. Pili R, Haggman M, Stadler WM, et al. A randomized, multicenter, international phase II study of tasquinimod in chemotherapy-naïve patients with metastatic castrate-resistant prostate cancer. J Clin Oncol 2010; 28(15 suppl):344s (abstract 4510).
24. McKeage MJ. The potential of DMXAA (ASA404) in combination with docetaxel in advanced prostate cancer. Expert Opin Investig Drugs 2008; 17:23-9.
25. McKeage MJ, Kelland LR. 5,6-dimethylxanthenoine-4-acetic acid (DMXAA) clinical potential in combination with taxane-based chemotherapy. Am J Cancer 2006; 5:155-62.
26. Pili R, Rosenthal MA, Mainwaring PN, et al. Phase II study on the addition of ASA404 (vadimezan; 5,6-dimethylxanthenone-4-acetic acid) to docetaxel in CRMPC. Clin Cancer Res 2010; 16:2906-14.
27. Figlin RA, Brown E, Armstrong AJ, et al. NCCN Task Force Report: MTOR inhibition in solid tumors. J Natl Compr Canc Netw 2008; 6(suppl 5):S1-20.
28. Morgan TM, Pitts TE, Gross TS, et al. RAD001 (everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid. Prostate 2008; 68:861-71.
29. Thomas G, Speicher L, Reiter R, et al. Demonstration that temsirolimus preferentially inhibits the mTOR pathway in the tumors of prostate cancer patients with PTEN deficiencies. Clin Cancer Res 2005 24:9132s..
30. Ross RW, Manola J, Oh WK, et al. Phase I trial of RAD001 and docetaxel in castration resistant prostate cancer with FDG-PET assessment of RAD001 activity. J Clin Oncol 2008; 26(15 suppl):266s (abstract 5069).
31. Gross ME, Soscia J, Sakowsky S, et al. Phase I trial of RAD001, bevacizumab, and docetaxel for castration-resistant prostate cancer (CRPC). J Clin Oncol 2009; 27( 15 suppl):272s (abstract 5154).
32. Armstrong AJ, Kemeny G, Turnbull JD, et al. Impact of temsirolimus and anti-androgen therapy on circulating tumor cell (CTC) biology in men with castration-resistant metastatic prostate cancer (CRPC): A phase II study. J Clin Oncol 2010; 28(15 suppl):43s (abstract TPS249).
33. Emmenegger U, Sridhar SS, Booth CM, et al. A phase II study of maintenance therapy with temsirolimus after response to first-line docetaxel chemotherapy in castration-resistant prostate cancer (CRPC). J Clin Oncol 2010; 28(suppl):15s (abstract TPS246).
34. Graff JR. Emerging targets in the Akt pathway for treatment of androgen-independent prostatic adenocarcinoma. Expert Opin Ther Targets 2002; 6:103-13.
35. Gera JF, Mellinghoff IK, Shi Y, et al. Akt activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression. J Biol Chem 2004; 279:2737-46.
36. Posadas EM, Gulley J, Arlen PM, et al. A phase II study of perifosine in androgen independent prostate cancer. Cancer Biol Ther 2005; 4:1133-7.
37. Yap TA, Patnaik, Fearen AI, et al. First-in-class phase I trial of a selective Akt inhibitor, MK2206, evaluating alternate day (QOD) and once weekly (QW) doses in advanced cancer patients with evidence of target modulation and antitumor activity. J Clin Oncol 2010; 28(15 suppl):235s (abstract 3009).
38. Raffo AJ, Perlman H, Chen MW, et al. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 1995; 55:4438-45.
39. Apakama I, Robinson MC, Walter NM, et al. Bcl-2 overexpression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer. Br J Cancer 1996; 74:1258-62.
40. Loberg RD, McGregor N, Ying C, et al. In vivo evaluation of AT-101 (R-gossypol acetic acid) in androgen-independent growth of VCaP prostate cancer cells in combination with surgical castration. Neoplasia 2007; 9:1030-7.
41. Jiang J, Sugimoto Y, Liu S, et al. The inhibitory effects of gossypol on human prostate cancer cells PC3 are associated with transforming growth factor β1 (TGFβ1) signal transduction pathway. Anticancer Res 2004; 24:91-100.
42. Liu G, Kelly WK, Wilding G, et al. An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer. Clin Cancer Res 2009; 15:3172-6
43. MacVicar GR, Curti B, Somer B, et al. An open-label, multicenter, phase I/II study of AT-101 in combination with docetaxel and prednisone in men with hormone refractory prostate cancer. Presented at: The American Society of Clinical Oncology: 2008 Gastrointestinal Cancers Symposium; February 14-16, 2008; San Francisco, CA. Abstract 152.
44. Zoubeidi A, Chi K, Gleave M. Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer. Clin Cancer Res 2010; 16:1088-93.
45. Humphreys DT, Carver JA, Easterbrook-Smith SB, et al. Clusterin has chaperone-like activity similar to that of small heat shock proteins. J Biol Chem 1999; 274:6875-81.
46. Zhang H, Kim JK, Edwards CA, et al. Clusterin inhibits apoptosis by interacting with activated Bax. Nat Cell Biol 2005; 7:909-15.
47. Zoubeidi A, Ettinger S, Beraldi E, et al. Clusterin facilitates COMMD1 and I-kappaB degradation to enhance NF-kappaB activity in prostate cancer cells. Mol Cancer Res 2010; 8:119-30.
48. July LV, Akbari M, Zellweger T, et al. Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. Prostate 2002; 50:179-88.
49. Miyake H, Nelson C, Rennie PS, et al. Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models. Cancer Res 2000; 60:2547-54.
50. Gleave M, Miyake H. Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemo-sensitivity in prostate cancer. World J Urol 2005; 23:38-46.
51. Sowery RD, Hadaschik BA, So AI, et al. Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy. BJU Int 2008; 102:389-97.
52. Chi KN, Siu LL, Hirte H, et al. A phase I study of OGX-011, a 2-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer. Clin Cancer Res 2008; 14:833-9.
53. Chi KN, Hotte SJ, Yu EY, et al. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2010; 28:4247-54.
54. Ryan BM, O'Donovan N, Duffy MJ. Survivin: A new target for anti-cancer therapy. Cancer Treat Rev 2009; 35:553-62.
55. Talbot DC, Davies J, Callies S, et al. First human dose study evaluating safety and pharmacokinetics of LY2181308, an antisense oligonucleotide designed to inhibit survivin. J Clin Oncol 2008; 26(15 suppl):157s (abstract 3518).
56. Satoh T, Okamoto I, Miyazaki M, et al. Phase I study of YM155, a novel survivin suppressant, in patients with advanced solid tumors. Clin Cancer Res 2009; 15:3872-80.
57. Chan JM, Stampfer MJ, Ma J, et al. Insulin-like growth factor-1 (IGF-1) and IGF binding protein-3 as predictors of advanced stage prostate cancer. J Natl Cancer Inst 2002; 94:1099-106.
58. Krueckl SL, Sikes RA, Edlund NM, et al. Increased insulin-like growth factor 1 receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model. Cancer Res 2004; 64:8620-9.
59. Kojima S, Inahara M, Suzuki H, et al. Implications of insulin-like growth factor-1 for prostate cancer therapies. Int J Urol 2009; 16:161-7.
60. Wu JD, Odman A, Higgins LM, et al. In vivo effects of the human type 1 insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors. Clin Cancer Res 2005; 11:3065-74.
61. Plymate SR, Haugk K, Coleman I, et al. An antibody targeting the type 1 insulin-like growth factor receptor enhances the castration-induced response in androgen-dependent prostate cancer. Clin Cancer Res 2007; 13:6429-39.
62. Rowinsky EK, Youssoufian H, Tonra JR, et al. IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor. Clin Cancer Res 2007; 13:5549s-55.
63. Higano C, Alumkal J, Ryan CJ, et al. A phase II study evaluating the efficacy and safety of single-agent IMC-A12, a monoclonal antibody against the insulin-like growth factor-1 receptor (IGF-IR), as monotherapy in patients with metastatic, asymptomatic castration-resistant prostate cancer. J Clin Oncol 2009; 27(15 suppl):269s (abstract 5142).
64. Gualberto A. Figitumumab (CP-751,871) for cancer therapy. Expert Opin Biol Ther 2010; 10:575-85.
65. Molife LR, Fong PC, Paccagnella L, et al. The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: Results of a phase Ib dose-escalation, open-label study. Br J Cancer 2010; 103:332-9.
66. Wheeler DL, Iida M, Dunn EF. The role of Src in solid tumors. Oncologist 2009; 14:667-78.
67. Araujo J, Logothetis C. Targeting Src signaling in metastatic bone disease. Int J Cancer 2009; 124:1-6.
68. Lombardo LJ, Lee FY, Chen P, et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino) thiazole-5-carboxamide, a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004; 47:6658-61.
69. Nam S, Kim D, Cheng JQ, et al. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res 2005; 65:9185-9.
70. Park SI, Zhang J, Phillips KA, et al. Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res 2008; 68:3323-33
71. Yu EY, Wilding G, Posadas E, et al. Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res 2009; 15:7421-8.
72. Araujo J, Armstrong AJ, Braud EL, et al. Dasatinib and docetaxel combination treatment for patients with castration-resistant progressive prostate cancer: A phase I/II study. J Clin Oncol 2009; 27(15 suppl):249s (abstract 5061).
73. Chang YM, Bai L, Liu S, et al. Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530. Oncogene 2008; 27:6365-75.
74. Lara PN, Jr, Longmate J, Evans CP, et al. A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: A California Cancer Consortium study. Anticancer Drugs 2009; 20:179-84.
75. Hangauer D, Gelman I, Dyster L, et al. Potent and selective in vitro and in vivo inhibition of tumor proliferation by KX01, a novel non-ATP competitive Src inhibitor. Proc Am Assoc Cancer Res 2007; (abstract 3245).
76. Bu Y, Gao L, Smolinsk M, et al. KX01 (KX2-391), a Src-family kinase inhibitor targeting the peptide-binding domain, suppresses oncogenic proliferation in vitro and in vivo. Proc Am Assoc Cancer Res 2008; (abstract 4983).
77. Adjei AA, Cohen RB, Kurzrock R, et al. Results of a phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket directed Src inhibitor, in patients with advanced malignancies. J Clin Oncol 2009; 27(15 suppl):148s (abstract 3511).
78. Ingham PW, McMahon AP. Hedgehog signaling in animal development: Paradigms and principles. Genes Dev 2001; 15:3059-87.
79. Karhadkar SS, Bova GS, Abdallah N, et al. Hedgehog signaling in prostate regeneration, neoplasia and metastasis. Nature 2004; 431:707-12.
80. Berman DM, Desai N, Wang X, et al. Roles for Hedgehog signaling in androgen production and prostate ductal morphogenesis. Dev Biol 2004; 267:387-98.
81. Sheng T, Li C, Zhang X, et al. Activation of the hedgehog pathway in advanced prostate cancer. Mol Cancer 2004; 3:29.
82. Shaw G, Price AM, Ktori E, et al. Hedgehog signaling in androgen independent prostate cancer. Eur Urol 2008; 54:1333-43.
83. Sanchez P, Hernandez AM, Stecca B, et al. Inhibition of prostate cancer proliferation by interference with sonic hedgehog-GLI1 signaling. Proc Natl Acad Sci USA 2004; 101:12561-6.
84. Lauth M, Bergstrom A, Shimokawa T, et al. Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists. Proc Natl Acad Sci USA 2007; 104:8455-60.
85. De Smaele E, Ferretti E, Gulino A. Vismodegib, a small-molecule inhibitor of the hedgehog pathway for the treatment of advanced cancers. Curr Opin Investig Drugs 2010; 11:707-18.
86. Rudin CM, Hann CL, Laterra J, et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med 2009; 361:1173-8.
87. Von Hoff DD, LoRusso PM, Rudin CM, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med 2009; 361:1164-72.
88. Kim J, Tang JY, Gong R, et al. Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth. Cancer Cell 2010; 17:388-99.
89. Chong CR, Xu J, Lu J, et al. Inhibition of angiogenesis by the antifungal drug itraconazole. ACS Chem Biol 2007; 2:263-70.
90. Xu J, Dang Y, Ren YR, et al. Cholesterol trafficking is required for mTOR activation in endothelial cells. Proc Natl Acad Sci USA 2010; 107:4764-9.
91. Nakayama T, Watanabe M, Suzuki H, et al. Epigenetic regulation of androgen receptor gene expression in human prostate cancers. Lab Invest 2000; 80:1789-96.
92. Welsbie DS, Xu J, Chen Y, et al. Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer. Cancer Res 2009; 69:958-66
93. Bradley D, Rathkopf D, Dunn R, et al. Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (NCI Trial 6862): Trial results and interleukin-6 analysis: A study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium. Cancer 2009; 115:5541-9.
94. Rathkopf DE, Chi KN, Vaishampayan U, et al. Phase Ib dose finding trial of intravenous panobinostat with docetaxel in patients with castration-resistant prostate cancer (CRPC). J Clin Oncol 2009; 27(15 suppl):250s (abstract 5064).
95. Rathkopf D, Wong BY, Ross RW, et al. A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer. Cancer Chemother Pharmacol 2010; 66:181-9.
96. Hoque MO. DNA methylation changes in prostate cancer: Current developments and future clinical implementation. Expert Rev Mol Diagn 2009; 9:243-57.
97. Stresemann C, Lyko F. Modes of action of the DNA methyltransferase inhibitors azacitidine and decitabine. Int J Cancer 2008; 123:8-13.
98. Festuccia C, Gravina G, D'Alessandro A, et al. Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models. Endocr Relat Cancer 2009; 16:401-13.
99. Sonpavde G, Aparicio AM, Delaune R, et al. Azacitidine for castration-resistant prostate cancer progressing on combined androgen blockade. J Clin Oncol 2008; 26(15 suppl):292s (abstract 5172).
100. Rouleau M, Patel A, Hendzel MJ, et al. PARP inhibition: PARP1 and beyond. Nat Rev Cancer 2010; 10:293-301.
101. Boss DS, Beijnen JH, Schellens JH. Inducing synthetic lethality using PARP inhibitors. Curr Clin Pharmacol 2010; 5:192-5.
102. Mendes-Pereira AM, Martin SA, Brough R, et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med 2009; 1:315-22.
103. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361:123-34.
104. Donawho CK, Luo Y, Luo Y, et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res 2007; 13:2728-37
105. Palma JP, Wang YC, Rodriguez LE, et al. ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumors. Clin Cancer Res 2009; 15:7277-90
106. Christensen SB, Skytte DM, Denmeade SR, et al. A Trojan horse in drug development: Targeting of thapsigargins towards prostate cancer cells. Anticancer Agents Med Chem 2009; 9:276-94.
107. Denmeade SR, Jakobsen CM, Janssen S, et al. Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer. J Natl Cancer Inst 2003; 95:990-1000.
108. Søhoel H, Jensen AM, Møller JV, et al. Natural products as starting materials for development of second-generation SERCA inhibitors targeted towards prostate cancer cells. Bioorg Med Chem 2006; 14:2810-5.
109. Vander Griend DJ, Antony L, Dalrymple SL, et al. Amino acid containing thapsigargin analogues deplete androgen receptor protein via synthesis inhibition and induce the death of prostate cancer cells. Mol Cancer Ther 2009; Epub ahead of print.